<DOC>
	<DOCNO>NCT02886598</DOCNO>
	<brief_summary>The purpose study assess safety efficacy Firmagon® ( degarelix ) injection condition general clinical practice Korea .</brief_summary>
	<brief_title>Safety Efficacy Firmagon® ( Degarelix ) Injection</brief_title>
	<detailed_description />
	<criteria>Patients eligible treatment Firmagon® ( degarelix ) injection accord approve product label , Firmagon® ( degarelix ) treatment decide study enrolment . Moreover , patient previously receive Firmagon® ( degarelix ) injection study commencement date site . Indication : treatment advance , hormonedependent prostate cancer . Patients previous concurrent know hypersensitivity component drug .</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>